Effect of Pioglitazone on Insulin Resistance and Atherosclerosis in Renal Allograft Recipients Without Diabetes

Yonsei University83 enrolled

Overview

The aim of this study was to evaluate the effect of pioglitazone treatment on insulin secretion, insulin resistance, and progression of atherosclerosis in renal allograft recipients without preoperative history of diabetes.

This is a prospective, randomized, open-label study. The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months. After treatment, we estimated insulin sensitivity index for transplantation,first phase and second phase insulin secretion, secretion area under the curve,and carotid intima-media thickness.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Kidney Transplantation Insulin Resistance Atherosclerosis

Interventions

PioglitazoneDRUG

The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Renal allograft recipients were eligible to participate in the study if they were aged ≥ 18 years, had no previous history of organ transplantation and were not currently using steroids or other immunosuppressants. Exclusion Criteria: * Diabetes before transplantation * Severe metabolic or infectious disease * Hepatic disease * Congestive heart failure (New York Heart Association II-IV) * Cadaver donor kidney donor transplantation * Unstable condition of the transplanted kidney

Locations (1)

Yonsei University College of Medicine

Seoul, South Korea

Outcomes

Primary Outcomes

Insulin Resistance and Insulin Secretion

Time frame: 1 year

Secondary Outcomes

carotid intima-media thickness

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.